ELD 680
Alternative Names: ELD-680Latest Information Update: 20 Sep 2023
At a glance
- Originator Eldec Pharmaceuticals
- Class Anti-inflammatories; Peptides
- Mechanism of Action ORAI1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 13 Sep 2023 Pharmacodynamics data from preclinical studies in Systemic inflammatory response syndrome released by Eldec Pharmaceuticals (Eldec Pharmaceuticals pipeline, September 2023)
- 12 Sep 2023 Preclinical development in Systemic inflammatory response syndrome in USA (IV), prior to September 2023 (Eldec Pharmaceuticals pipeline, September 2023)
- 12 Sep 2023 Preclinical trials in Sepsis in USA (IV)